



**CEDARS-SINAI HEALTH SYSTEM  
VICE PRESIDENT OF CEDARS-SINAI CANCER  
Cedars-Sinai Cancer  
Los Angeles, California**

**THE SEARCH**

Cedars-Sinai Health System (Cedars-Sinai) seeks an experienced, highly collaborative, and innovative leader to serve as the Vice President of Cedars-Sinai Cancer (CSC), the largest academic cancer care provider in California. While joining Cedars-Sinai at this pivotal moment in the expansion of its clinical footprint and resulting program growth, the Vice President will have the opportunity to directly influence both the delivery of excellent pediatric and adult cancer care and the conduct of ground-breaking research that fuels that care.

To that end, the Vice President (VP) is slated with overseeing and supporting all clinical and research operations related to cancer care at Cedars-Sinai. To do so effectively, the VP will partner closely with the Director of Cedars-Sinai Cancer Center, the Chairs of the Department of Medicine, the Department of Radiation Oncology, and the Department of Surgery, as well as the Directors of Basic, Translational and Clinical Research. Reporting in a matrixed structure to the EVP and Chief Operating Officer; the EVP of the Medical Network; and the EVP and Dean of the Faculty, the VP will lead the successful integration of all cancer services by developing and applying a seamless continuum of care model.

Within the clinical arena, the VP will set forth policies and procedures that facilitate strategic network development while both ensuring strong financial performance and maintaining excellent standards in quality and safety, and patient access and experience. In supporting the on-going growth of all cancer research, the VP will ensure that the operations driving cancer program certifications and designation requirements, cancer registries, and cancer tumor boards serve to support and sustain the fuller integration of basic, translational, population, and clinical research.

The Vice President of Cedars-Sinai Cancer will bring significant experience as a leader of cancer services, preferably in a complex multi-site system, that includes the integration of services in a manner that equally supports the conduct of research as well as the delivery of care. A well-honed collaborative, thoughtful and innovative approach to leading both by influence and command is required as is the ability to pivot and adapt to an ever-changing environment.

Cedars-Sinai is a nonprofit academic healthcare organization serving the diverse Los Angeles community and beyond. With pioneering medical research achievements, education programs defining the future of healthcare, and wide-ranging community benefit activities, Cedars-Sinai is

setting new standards for quality and innovation in patient care. With a mission to elevate the health status of the communities they serve, Cedars-Sinai provides expert care for over 60 types of cancer, facilitating over 238,000 patient visits in FY2022 at more than 10 locations throughout the region.

*Cedars-Sinai has retained the national executive search firm Isaacson, Miller to assist in the search. All applications, inquiries, and nominations, which will remain confidential, should be directed to the search firm as indicated at the end of this document.*

## **ABOUT CEDARS-SINAI HEALTH SYSTEM**

Since its beginning in 1902 as Cedars-Sinai Medical Center, Cedars-Sinai has focused on its mission of meeting the healthcare needs of one of the most diverse regions in the nation, continually setting new standards in quality and innovation in patient care, research, teaching, and community service. This mission has further evolved through the establishment of an expanding regional healthcare system, Cedars-Sinai Health System. The system's 4,500 physicians and nurses currently provide care for more than 1 million people each year at three of the best hospitals in Southern California: Cedars-Sinai Medical Center, Torrance Memorial Hospital and Marina Del Ray Hospital, representing more than 1,420 licensed beds with revenue exceeding \$6 billion annually. In addition, at its more than 50 outpatient locations spanning the entire Los Angeles region, the system seamlessly provides superior outpatient, acute, and sub-acute patient care; conducts breakthrough biomedical research projects; grants degrees in graduate and undergraduate medical education; and develops and implements impactful community service programs.

For more a comprehensive description of Cedars-Sinai Health System, including its robust research enterprise and stellar education programs, see the addendum at the end of this document.

## **ABOUT CEDARS-SINAI CANCER**

Cedars-Sinai Cancer is the largest academic cancer care provider in California, treating more than 20,000 new patients every year, and is now a fully integrated research and service line enterprise. Clinically, it provides medical, surgical, and radiation treatment for a wide range of adult and pediatric cancers delivered by over 100 clinical providers that include 75 faculty supported by more than 500 staff.

Building on their scientific success in other fields, Cedars-Sinai established the Samuel Oschin Comprehensive Cancer Institute (SOCCI) in 2004. The mission of SOCCI was to expedite translational research and cutting-edge clinical trials based on their research of the role of genes and the environment in cancer; identification of the molecular causes of cancer and development of drugs to target molecular pathways; and the identification and development of effective

imaging and pathology technology for early detection. The term “comprehensive” in the formal title reflected the intent to include all existing and future cancer activities under the umbrella of the Institute, as opposed to indicating that the portfolio of cancer research covered everything that would be necessary by modern standards.

Today, Cedars-Sinai Cancer, in its totality, is comprised of more than 500 faculty and community providers practicing at:

- Samuel Oschin Comprehensive Cancer Institute
- Cedars-Sinai Cancer – Beverly Hills
- The Angeles Clinics and Research Institute
- The Hunt Cancer Center at Torrance Memorial Medical Center
- Cedars-Sinai Valley Oncology Medical Group
- Huntington Cancer Center, an affiliate of Cedar-Sinai Cancer

Radiation Oncology is provided through Cedars-Sinai Medical Center, Radiation Oncology of Beverly Hills, and Radiation Oncology of Tarzana. The cancer service line has a total gross revenue of over \$630 million, net revenue of about \$191 million, and professional revenue of about \$23 million. Budgeted expenses are approximately \$159 million, not including non-operational funds or clinical and research grant funding.

## **THE INTERPLAY BETWEEN RESEARCH AND CLINICAL CARE**

Cedars-Sinai Cancer, ranked #14 by USNWR, is recognized for outstanding cancer care built on a foundation of innovation and leading-edge research. Compassionate care is integrated with an agile research enterprise, giving patients access to pioneering treatments. A core mission of the Institute is to quickly turn research findings into safe, useful therapies. The Institute supports basic and clinical research in many cancer-related areas, including blood cell development, gene cloning, and stem cells, and continues to build programs in key areas of strength such as genitourinary cancers, women’s cancers, and experimental therapeutics. It is working to develop new programs in critical areas such as cancer prevention.

## **COMMUNITY OUTREACH AT CEDARS-SINAI CANCER**

Cedars-Sinai maintains a global footprint, but the core of its mission is based in Los Angeles. Cedars-Sinai’s outreach efforts are as diverse as the region it serves and illustrate the institution’s commitment to empowering people to live healthier lives. Community Outreach and Engagement (COE) at Cedars-Sinai Cancer is dedicated to reducing the cancer burden in the city that has served as its home for more than a century, engaging communities with services and programs that include free education, screening, and immunization programs; research aimed at improving health outcomes in underserved neighborhoods; and partnerships with community organizations that enhance the health of Angelenos. This deeply ingrained tradition of

community service drives Cedars-Sinai to provide care for those with the greatest need, including uninsured and underinsured individuals and families, as well as Medi-Cal and Medicare patients.

## **THE ROLE OF THE VICE PRESIDENT OF CANCER**

As the overarching executive of the Cedar-Sinai Cancer service line, the Vice President is responsible for its continued strategic growth and for maintaining its standards of excellence in cancer care delivery and research. The VP will therefore work collaboratively with other senior leaders and administrators to seamlessly advance and direct all operations in transitions between and amongst all clinical and research programs, treatments and services. To achieve this consistent and equal delivery model across the entire system, the VP will be responsible for the following initiatives and functions:

- Further developing and integrating the ambulatory network
- Developing and implementing operation efficiencies that support clinical trial accruals and other research initiatives
- Supporting and encouraging the equitable yet site-specific distribution of graduate medical education programs across the system
- Recruiting and retaining physicians, scientists, and staff by providing innovative and relevant opportunities for employee engagement and professional development

In achievement of these goals, the VP is supported by and leads four direct reports:

- Associate Director Quality Services, Service Line Operations
- Executive Director and Associate Director for Administration, Cedars-Sinai Cancer
- Executive Director, Cancer Clinical Trials Office
- Executive Director, Cancer Clinical Operations, Samuel Oschin Comprehensive Cancer Center

These four direct reports ensure the effective operational functioning of both adult and pediatric ambulatory cancer services while a matrix reporting structure applies to providers, some of whom report to the CCSC director, department chairs, and/or medical network with some inpatient reporting to the CEOs or COOs of system hospitals.

To deliver on this mandate, the next VP must bring significant successful experience as a leader over cancer services, particularly in a complex multi-site system that includes inpatient and ambulatory experience, achieved through a highly collaborative approach toward programmatic development. A key initiative will involve working in tandem with the Cedars-Sinai Cancer director to integrate basic, translational, and clinical research - including population science - with clinical cancer care across the system. In addition, the VP will support and assist in the success accreditation processes which include those for the Commission on Cancer (COC), the

National Accreditation Program for Breast Centers (NAPBC), the Accreditation Program for Excellence and Radiation Oncology (APEX) and the Federation Accreditation of Cellular Therapies (FACT). Importantly, the Vice President will work with the Cedars-Sinai Cancer director in the quest to obtain and maintain NCI designation.

## **OPPORTUNITIES AND CHALLENGES OF THE NEXT VICE PRESIDENT OF CANCER**

The Vice President of Cedars-Sinai Cancer will be a strategic, service-oriented, thoughtful leader with exceptional collaborative skills who will apply strong assessment and implementation skills to addressing and/or furthering the following opportunities and challenges:

### ***Coordinate and execute a compelling strategy to further develop and expand Cedars-Sinai Cancer care and research efforts during a period of substantial growth***

The next Vice President will develop a strategic, synergistic vision that aligns with the transformative change and rapid expansion of Cedars-Sinai Health System, while fostering the full integration of cancer care across the system with a focus on high quality patient care and cutting-edge research. As such, the VP will work collaboratively within Cedars-Sinai and beyond to fortify Cedars-Sinai Cancer's position and reputation regionally and nationally in cancer care.

The VP also serves as a strategic advisor to Cedars-Sinai Cancer leadership regarding the overall financial and operational performance of cancer services, ensuring alignment with mission, strategy and goals.

### ***Provide leadership for the practice of cancer, the delivery of ambulatory operations and outpatient cancer care in a uniform, standardized way across Cedars-Sinai Cancer***

The next Vice President will drive both clinical and research excellence within the Cedars-Sinai Cancer service line by assessing, creating and implementing innovative cancer services across the care continuum. Expanding upon the work of the previous VP in close partnership with the Director and Deputy Director of Cedars-Sinai Cancer, the next VP will further develop existing and potentially new network affiliations based on jointly developed regional strategies. At all times, the overarching goal is the further development of and integration of programmatic access across the system.

### ***In coordination with the Cedars-Sinai Cancer director, integrate the conduct of basic, translational, clinical and population health research within the delivery of clinical cancer care across the system***

The VP is the senior administrative leader- either directly or indirectly - for all of Samuel Oschin Comprehensive Cancer Institute's patient care services including radiation oncology, infusion and patient support services housed within the departments of Medicine, Surgery and Imaging. In addition, the VP will work in alignment and collaboration with the Cedars-Sinai Clinical Trials Administration, the Samuel Oschin Comprehensive Cancer Institute's Clinical Trials Office and the Cedars-Sinai Cancer Executive Committee, in implementing clinical operations that facilitate and support the application and access to clinical trials across all entities of the Health System for Cedars-Sinai Cancer and its affiliates.

***Support the cancer center in their ongoing effort to achieve National Cancer Institute designation***

In collaboration with the Cedars-Sinai Cancer Director, the VP plays a pivotal role in the ongoing effort to achieve NCI designation and formalize their position as a national leader in cancer treatment, research and education. The VP works with other Cancer leadership to ensure the administrative structure efficiently and sustainably supports NCI associated accreditation, comprehensive research activities, extramural research funding and training and regulatory affairs initiatives.

***Establish and maintain a robust and effective leadership culture centered on transparency, accountability, and collegiality across Cedars-Sinai Cancer and the health system***

A collaborative and results driven leader, the VP will leverage existing relationships and nurture new ones that both support the Cedars-Sinai Cancer mission and address the needs of the expanding system and those in their catchment area. The VP will have the ability to lead by influence, leading culture change and changing structures, workflows, and policies where necessary while communicating effectively and ensuring transparency regarding critical decisions.

**QUALIFICATIONS AND EXPERIENCE**

The successful candidate will be one who has earned a master's degree in either business or healthcare administration and has significant leadership experience in cancer services, preferably within a complex, high-performing, multi-hospital health system. Broad based upper-level management experience facilitating and coordinating a wide range of activities within cancer services across the health system is expected as is a knowledge of contemporary practice challenges, national trends, and other key drivers in achieving excellence in patient quality and safety and patient engagement in a highly competitive healthcare marketplace.

And as importantly – given the high level of leadership required in this senior level role – it is imperative that the VP brings an ingrained commitment to advancing and promoting academic excellence as evidenced by prior work with and in support of physician scientists, academic

researchers and allied health professionals founded on a deep understanding of research, clinic and hospital operations, finance, and communication modalities. To achieve this mission, the VP must possess most of the following skills and competencies:

- A track record of leadership that includes developing, planning, and successfully leading strategic growth initiatives in cancer research and care, ideally within a highly competitive healthcare landscape.
- A proven commitment to promoting an open, inclusive, high trust, collaborative environment dedicated to patient- and family-centered care, including the application of principles supporting a fair and inclusive culture that welcomes diversity of thought and insight in alignment with the health system's strategic plans.
- A philosophical framework that emphasizes the value of communication, service, transparency, and teamwork.
- A leadership style that is proactive, visible, and respected that engenders support from leaders, providers, and staff to accomplish the vision and goals of the organization.
- Ability to respectfully hold others accountable and create a culture that champions learning and performance improvement.
- Flexibility and ability to work effectively in a complex and fluid environment.
- A consensus-building leadership style capable of unifying disparate groups towards the achievement of a common goal (e.g. obtaining NCI Designation).
- A high degree of emotional intelligence and interpersonal skills that serve to build meaningful working alliances across the organization.

## TO APPLY

For more information, or to submit nominations, inquiries or applications, please contact:

Patricia Hastie, Managing Partner  
Jasmine Miller, Senior Associate  
Sarah Sweeney, Search Coordinator  
Isaacson, Miller

<https://www.imsearch.com/open-searches/cedars-sinai-health-system/vice-president-cedars-sinai-cancer>

*Successful candidates must agree to a background check to be performed as a condition of employment.*

*Cedars-Sinai is an Equal Opportunity Employer.*

---

## **Appendix**

### **Cedars-Sinai Health System**

Cedars-Sinai system consists of three award-winning hospitals throughout the Los Angeles region: Cedars Sinai Medical Center; Marina Del Ray Hospital; and Torrance Memorial Medical Center.

The system's flagship hospital, Cedars-Sinai Medical Center, is ranked number 7 in the country by US News and World Report. Six clinical service lines (Heart, Orthopedics, Gastroenterology/GI Surgery, Lung/Lung Surgery, Cancer, and Gynecology) are the highest rated service lines on the West Coast. Cedars-Sinai has received the National Research Corporation's Consumer Choice Award 18 years in a row for providing the highest quality medical care in Los Angeles and boasts the longest running Magnet designation for nursing excellence in California.

With an annual net revenue of \$4.3 billion and 890 licensed beds, Cedars-Sinai Medical Center employs 2,200 physicians, 3,000 nurses, and thousands of other healthcare professionals and staff. Clinical programs range from primary care to quaternary specialist treatments for rare, complex, and advanced illnesses.

In addition to Cedars-Sinai Medical Center, the health system is home to two other award-winning hospitals. Located to the west of Cedar-Sinai's flagship hospital, Marina del Rey Hospital is a 133-bed surgical hospital. The Hospital concentrates on four areas of expertise: spine, weight loss, orthopedics and minimally invasive surgery. Marina del Rey Hospital is fully accredited and nationally recognized by the Joint Commission for safe and effective quality care.

Torrance Memorial Medical Center is a 512-bed, nonprofit medical center established to provide quality health care services predominantly to the residents of the South Bay, Peninsula and Harbor communities. In 2018, Torrance Memorial affiliated with Cedars-Sinai under the umbrella of Cedars-Sinai Health System to further enhance access, coordination and quality of care, and to bring more expertise in the areas of neuroscience, cancer and heart failure to the communities of the South Bay.

In addition, Cedars-Sinai serves the community through its Medical Network and the highly rated Cedars-Sinai Medical Group and Cedars-Sinai Health Associates, which include CS Cancer Beverly Hills, Huntington Cancer Center (an affiliate of CS Cancer), The Angeles Clinics and Research Institute, The Cedars-Sinai Valley Oncology Medical Group, Kerlan-Jobe Institute, Beverly Pathology, Beverly Anesthesiology, Santa Monica Gastroenterology, Universal Cardiology



Medical Group, and Valley Internal Medicine. Cedars-Sinai also has joint venture collaborations to offer ambulatory surgery and inpatient and outpatient rehabilitation care in Ambulatory Surgery Centers and at the Cal Rehabilitation Institute.

Cedars-Sinai is a hub for biomedical research, with over \$100 million in annual NIH awards, and runs a Graduate School and is a training center for future physicians and other healthcare professionals. Cedars-Sinai attracts exceptional talent, including world-renowned physician-scientists who seek a place where they can both conduct research and treat patients. Cedars-Sinai's patients benefit from access to outstanding specialists and from researchers who have an ideal community in which to study the impact of healthcare challenges and reflect that knowledge in their patient-focused research. The total community benefit for Cedars-Sinai Health System is \$823 million.

In addition, Cedars-Sinai has teamed with Taikang Healthcare to develop a new, world-class hospital in Shenzhen, China. The hospital, which will be a public-private partnership in the Qianhai central business district, will house 500 to 1,000 beds. Cedars-Sinai will provide education, guidance and expertise in quality, safety and personalized care as the two institutions work toward a long-term relationship. Partners also include the Qianhai Authority — the government entity that manages the Qianhai district — and the Southern University of Science and Technology, a research university and medical school in Shenzhen.

## **RESEARCH AT CEDARS-SINAI HEALTH SYSTEM**

Discovery is central to Cedars-Sinai's mission of promoting health, reducing suffering, and improving human life. The more than 2000 research projects currently underway explore the range of medical research from the fundamental study of disease pathogenesis to population healthcare delivery. Robust research platforms include exploration of stem cells, genomics, immunology, imaging, proteomics, bacteriomics, genetics and bioinformatics, and actively support frontiers of biomedicine investigation in cardiac care, cancer, transplantation, orthopedics, digestive health, neurosciences, women's health, metabolism, and more. Cedars-Sinai's current extramural research funding is over \$215 million with half of that coming from the NIH, ranking Cedars-Sinai 9<sup>th</sup> in the nation in NIH funding among independent hospitals.

Cedars-Sinai is home to 18 departments housing 550 faculty in anesthesiology, biomedical sciences, cardiac surgery, cardiology, computational biomedicine, imaging, medicine, neurology, neurosurgery, obstetrics and gynecology, orthopedics, pathology and laboratory medicine, pediatrics, physical medicine and rehabilitation, psychiatry and behavioral neurosciences, radiation oncology, surgery and urology. With experts in ground-breaking areas of research and clinical care, Cedars-Sinai also includes the following institutes:

- Board of Governors Regenerative Medicine Institute
- Geri and Richard Brawerman Nursing Institute

- Samuel Oschin Comprehensive Cancer Institute
- Smidt Heart Institute
- Women's Guild Lung Institute
- Biomedical Imaging Research Institute
- Advanced Clinical Biosystems Research Institute
- F. Widjaja Inflammatory Bowel and Immunobiology Research Institute
- Maxine Dunitz Neurosurgical Institute
- Kao Autoimmunity Institute
- Human Microbiome Research Institute
- Diabetes and Obesity Research Institute.

## **EDUCATION AT CEDARS-SINAI HEALTH SYSTEM**

As one of the leading freestanding academic medical centers in the country, education at Cedars-Sinai combines rigorous academic curricula with mentorship from globally recognized faculty.

The Cedars-Sinai Graduate School awards PhD and MS degrees in Biomedical Sciences and offers a unique, structured experience in translational research and clinical practice. Graduate medical education programs include 13 residency and 77 fellowship programs, totaling nearly 500 participants while a robust undergraduate medical education program in all disciplines provides 850 medical student rotations at Cedars-Sinai multiple hospitals and community sites. The school also boasts a highly diverse and inclusive student population that is reflective of the community it serves with 25% of enrolled PhD students over the last 12 years belonging to under-represented groups.

The School's clinical scholars program is geared towards junior physicians looking to become clinical scientists, nurses seeking advanced training, and those looking to become allied health professionals. And as part of Cedar-Sinai's burgeoning research portfolio, postdoctoral scientists and other junior researchers fulfill a critical role in expanding the horizons of biomedical research. Home to several T32 training grants, Cedars-Sinai prides itself on preparing 160 postdoctoral students through its robust education, training and mentorship programs. Cedars-Sinai further supports the ongoing medical education process as a sustaining member of the National Postdoctoral Association, which actively encourages postdoctoral students to pursue careers in academia, industry or other research-related areas.

### **Cedars Sinai Cancer Leadership**

**Bryan Croft**

**Executive Vice President and Chief Operating Officer of Cedars-Sinai Medical Center,**

In his role as EVP and COO, Croft is leading day to day operations and overseeing all service line and clinical support services with the goal of ensuring the delivery of high-quality, effective and efficient patient care. He also serves as CEO of Cedars-Sinai Marina del Rey Hospital.

Croft joined Cedars-Sinai in 2010 as vice president of Operations and was promoted to senior vice president of Operations in 2017. He has been instrumental in advancing Cedars-Sinai's operations and developing clinical programs and services, working collaboratively with department chairs, senior management and medical staff. His leadership accomplishments include operational and strategic oversight of the Smidt Heart Institute at Cedars-Sinai and the Cedars-Sinai Comprehensive Transplant Center, the planning process for the Cedars-Sinai Marina del Rey Hospital replacement facility, and expansion and establishment of new clinical programs.

Prior to Cedars-Sinai, Croft served as Vice President of Operations for Houston Methodist Hospital, and before that was vice president of Operations for The Queen's Medical Center in Honolulu. He is a fellow of the American College of Healthcare Executives, was a board member of the American College of Healthcare Executives' Greater Houston and Southern California Chapters, and served on the Regent's Advisory Council in Honolulu. He recently served as a board member of the Alumni Association of the Trinity University Department of Health Care Administration.

Croft earned a bachelor's degree in business administration from Texas Tech University and a master's degree in health care administration from Trinity University.

**Jill Martin**  
**Executive Vice President, Cedars-Sinai Medical Center**

Jill Martin joined Cedars Sinai as Vice President of Finance for the Medical Network in 1999. In addition to overseeing financial management of the organization, she led numerous initiatives to increase the capabilities of the Medical Network's information systems to enhance evidence-based clinical and financial decisions. She also assumed responsibility for the organization's physician recruitment, medical practice acquisitions, managed care operations, human resources, risk management and compliance.

In 2016, Martin advanced to Senior Vice President and Chief Operating Officer for the Medical Network, reflecting increased responsibilities as the organization grew. In collaboration with her colleagues on the leadership team, she led the development and implementation of a comprehensive strategic and financial plan that has positioned the Medical Network to successfully meet the challenges of value-based care.

As Executive Vice President, Martin oversees the Medical Network, which now includes more than 1,000 physicians and 2,000 staff members who provide healthcare to patients, with more than 1 million patient visits annually. The organization also manages numerous Cedars-Sinai

specialty practices and services throughout Los Angeles County, including ambulatory surgery centers, joint venture imaging and physical therapy centers. Additionally, the Medical Network recently began partnering with Cedars-Sinai's newest affiliate, Huntington Health, in a number of specialty programs.

Martin is also active in community and professional organizations. She serves on the CFO Council as well as the Women in Leadership Council of the American Medical Group Association and is active in Women in Healthcare Administration of Southern California. She also served on the board of Imagine LA, a community organization dedicated to ending the cycle of family homelessness in Los Angeles.

**Shlomo Melmed, MB, ChB,  
Executive Vice President of Academic Affairs and Dean of the Medical Faculty, Cedars-Sinai  
Medical Center**

Dr. Melmed, MB, ChB, has pioneered the discovery and application of novel treatments for endocrine tumors in his NIH-funded laboratory, where he investigates molecular mechanisms and new treatments for pituitary tumors and related hormonal disorders.

Dr. Melmed, who also holds the Helene A. and Philip E. Hixon Distinguished Chair in Investigative Medicine at Cedars-Sinai, has authored more than 350 articles in prestigious peer-reviewed journals. As a gifted educator, Dr. Melmed has also trained more than 80 physicians, scientists and graduate students. He plays a major role in leading the growth of research and educational programs at Cedars-Sinai, which is now one of the nation's top-tier non-university academic medical centers.

Dr. Melmed received his medical degree with distinction from the University of Cape Town, School of Medicine. He is a diplomat of the American Board of Internal Medicine, certified in Endocrinology and Metabolism; a Master of the American College of Physicians; an elected member of the Association of American Physicians and the American Society of Clinical Investigation; recipient of the Endocrinology Medal of the Royal Society of Medicine; the Endocrine Society Clinical Investigator Award; the Society of Endocrinology Transatlantic Medal; Ipsen Foundation Endocrine Regulation Award; the Pituitary Society's Lifetime Achievement Award, and is listed in BEST Doctors of America. At Cedars-Sinai, Dr. Melmed has spearheaded major academic growth and development by recruiting talented nationally recognized faculty leadership, establishing new programs and maintaining standards of excellence for educational programs. His executive leadership continues to maintain Cedars-Sinai as a top tier academic medical center.

**Dan Theodorescu, MD, PhD  
Director, Cedars Sinai Cancer**

In addition to serving as Director of the Samuel Oschin Comprehensive Cancer Institute, Dr. Theodorescu is also the director of Cedars Sinai Cancer, the entire Cedars-Sinai Health System cancer enterprise. Prior to joining Cedars in 2018, he served as director of the University of Colorado Cancer Center since 2010 where he held an appointment as a distinguished university professor.

Dr. Theodorescu is known for his work on the molecular mechanisms underlying bladder cancer and tools that determine drug response as well as the discovery of new drugs for cancer. Examples include the discovery of genes that regulate tumor growth and metastasis and novel biomarkers and concepts for precision therapeutic approaches such as the COXEN principle, that are currently being tested in national (SWOG 1314) clinical trials. He also conceptualized the approach and then led the discovery and development of a “first in class” RalGTPase inhibitor as a new therapeutic in cancer. This drug was awarded a US patent and is in commercial development. Most recently he identified approaches that define effective combination therapy with checkpoint inhibitors.

Dr. Theodorescu has published over 300 articles including articles in Nature, Science, Cancer Cell, PNAS, and JCI. His laboratory is funded by grants from the NIH-NCI. Dr. Theodorescu is the founding co-editor in chief of Bladder Cancer, the first journal focused on this disease and an elected member of the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP), the American Association of Genitourinary Surgeons (AAGUS), the American Surgical Association (ASA) and the National Academy of Medicine (NAM). He also serves on the Board of Scientific Counsellors of the National Cancer Institute (NCI) of the United States of America.

**Robert Figlin, MD, FACP  
Deputy Director, Samuel Oschin Comprehensive Cancer Institute**

In addition to serving as Deputy Director, Dr. Figlin is the Steven Spielberg Family Chair in Hematology Oncology and a Professor of Medicine and Biomedical Sciences. Dr. Figlin received his medical degree from the Medical College of Pennsylvania and completed his residency and chief residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in hematology/oncology at the David Geffen School of Medicine at UCLA. He is an Emeritus Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA. Prior to joining Cedars-Sinai, Dr. Figlin was the Arthur and Rosalie Kaplan Endowed Chair of the Department of Medical Oncology and Therapeutics Research, and the Associate Director for Clinical Research at the City of Hope Comprehensive Cancer Center.

Dr. Figlin serves as Editor for Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, Lancet, JNCI, Lancet Oncology, and Journal of Urology, among others. He has authored over 400 peer reviewed articles, more than 70 book chapters, and has published as editor multiple books

in kidney cancer. A nationally recognized leader in genitourinary and thoracic oncology, Dr. Figlin's research focuses on renal cell carcinoma and thoracic malignancies. He established and directed the Kidney Cancer Program at Cedars-Sinai Medical Center, which aims to understand the biology of kidney cancer and translate that knowledge into novel treatment approaches. His leadership in developing novel anticancer drugs that avoid the toxicity associated with standard treatments furthers Cedars-Sinai's tradition of compassionate patient care.